Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Bumble Inc (BMBL) Price & Performance

Adaptive Biotechnologies CorpTrade
Bumble IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Bumble Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Bumble Inc trades at $2.64 (market cap $366.87M). The key difference: Adaptive Biotechnologies Corp is far larger — about 11× Bumble Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.

ADPTBMBL
Market Cap
$4.04B$366.87M
Sector
HealthTechnology
52-Week High
$25.45$7.17
52-Week Low
$12.30$2.70
Enterprise Value
$4.10B$672.73M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.

Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.

Bumble Inc

Bumble (BMBL) trades at $2.62, down 4.03% on the day, reflecting ongoing investor concerns. The stock is in a bearish technical trend with negative earnings and declining revenue. Recent strategic shifts, including removing the women-first messaging rule and exploring a sale, aim to revive growth amid falling paying users. Valuation ratios like P/S of 0.38 and P/B of 0.71 appear low, but profitability remains weak with a net income margin of -57.96%.

The outlook is cautious; while cost controls and product changes could stabilize the business, persistent losses and competitive pressures pose significant risks. Analyst consensus is mixed with a $3.62 price target, but high institutional selling and bearish sentiment suggest limited near-term upside. Investors should weigh potential turnaround against execution risks and market skepticism.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Bumble Inc

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.

Read more on BMBL